Search - tctmd.com

Displaying 561 - 580 of 807

Sort: Relevancy | Date

Presentation TCT 2014

Current Status of Acute Stroke Therapy: Trials, Tribulations, and Practical Issues

Presenter: Leo Nelson Hopkins, Sriram S. Iyer, Zvonimir Krajcer, Adnan Siddiqui

September 13, 2014

Presentation TCT 2014

The Clinical Trialists Perspective on the Evidence and Certainty: How Should It Influence Regulatory Decisions, Clinical Practice, and Guidelines?

Presenter: Matthew J. Price, Mark Reisman, Sheldon Goldberg, Sanjay Kaul

September 13, 2014

Presentation TCT 2014

Dissecting the Evidence: Is There Anyone with Stroke Who Can Benefit from PFO Closure?

Presenter: Matthew J. Price, Mark Reisman, Sheldon Goldberg, John D. Carroll

September 13, 2014

Presentation TCT 2014

ASA/AHA Guidelines 2014: PFO Closure for Cryptogenic Stroke Is Now Class III LOE A! Is This the Final Word from the Neurology Community?

Presenter: Matthew J. Price, Mark Reisman, Sheldon Goldberg, David E. Thaler

September 13, 2014

Presentation TCT 2014

Meta-analyses of PFO Closure Trials for Stroke: What Is the Evidence?

Presenter: Matthew J. Price, Mark Reisman, Sheldon Goldberg, Abel Romero-Corral

September 13, 2014

Presentation

Trends in Hospitalization and Outcomes for Acute CVD and Stroke, 1999-2011

Presenter: Harlan M. Krumholz

August 29, 2014

Presentation

Predictors of Recurrent Events in Patients with Cryptogenic Stroke and PFO in the CLOSURE I Trial

Presenter: S. Elmariah

August 20, 2014

Presentation LAA 2014

Left Atrial Appendage Closure (LAAC) for Stroke Prevention in Non-Valvular AFib: My Preferred Frontline Therapy

Presenter: Maurice Buchbinder

July 19, 2014

Presentation LAA 2014

Quantifying stroke and bleeding risk in atrial fibrillation

Presenter: Stefan Bertog

July 17, 2014

Presentation LAA 2014

AF Basics:Etiology, Prevalence & Risk of Stroke

Presenter: Shephal Doshi

July 17, 2014

Presentation

Cryptogenic Stroke and Underlying A-fib

Presenter: Tomasso Sanna

July 01, 2014

Presentation

A-fib in Patients with Cryptogenic Stroke or TIA

Presenter: D.J. Gladstone

July 01, 2014

Presentation

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

Presenter: David R. Holmes Jr.

June 30, 2014

Presentation

National Trends in Stroke after AMI: 1999-2010

Presenter: Y. Wang

June 27, 2014

Presentation

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

Presenter: Robert P. Giugliano

June 24, 2014

Presentation TVT 2014

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Presenter: Axel Linke

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will Become the Standard of Care

Presenter: Eberhard Grube

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Has Stroke Frequency Declined After TAVR?

Presenter: Nicolas M. van Mieghem

June 07, 2014

Advertisement

Current Status of Acute Stroke Therapy: Trials, Tribulations, and Practical Issues

The Clinical Trialists Perspective on the Evidence and Certainty: How Should It Influence Regulatory Decisions, Clinical Practice, and Guidelines?

Dissecting the Evidence: Is There Anyone with Stroke Who Can Benefit from PFO Closure?

ASA/AHA Guidelines 2014: PFO Closure for Cryptogenic Stroke Is Now Class III LOE A! Is This the Final Word from the Neurology Community?

Meta-analyses of PFO Closure Trials for Stroke: What Is the Evidence?

Trends in Hospitalization and Outcomes for Acute CVD and Stroke, 1999-2011

Predictors of Recurrent Events in Patients with Cryptogenic Stroke and PFO in the CLOSURE I Trial

Left Atrial Appendage Closure (LAAC) for Stroke Prevention in Non-Valvular AFib: My Preferred Frontline Therapy

Quantifying stroke and bleeding risk in atrial fibrillation

AF Basics:Etiology, Prevalence & Risk of Stroke

Cryptogenic Stroke and Underlying A-fib

A-fib in Patients with Cryptogenic Stroke or TIA

PREVAIL: Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients with A-fib vs Long-term Warfarin Therapy

National Trends in Stroke after AMI: 1999-2010

Cerebrovascular Events in 21,105 Patients with A-fib Randomized to Edoxaban Versus Warfarin

A Critical Analysis of Present Data on Cerebral Protection after TAVR

Why Cerebral Protection after TAVR Will Become the Standard of Care

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Has Stroke Frequency Declined After TAVR?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content